The Global Patent Exchange

Web: www.tynax.com |  Phone: (650)292-4849 |  Email: contact@tynax.com

Patent for License:

Pharmaceutical Composition for Inhibiting Corneal, Retinal Angiogenesis, and other Organs    

Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal

Overview

A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitreal or subconjuntival means or under the form for topical administration.

The pharmaceutical compound could be applied in oncological diseases as in colorectal and breast cancer as well as in several ophthalmological diseases (diabetic retinopathy, exudative age related macular degeneration, corneal neovascularization by different causes)

Primary Application of the Technology

Health care market: oncology and ophthalmology.

The Problem Solved by the Technology

The new drug inhibits angiogenesis (neovascularization), a process present in several ophthalmological and oncological diseases

How the Technology Solves the Problem

The drug associated to Poloxamer 307 or to nanoparticles showed a longer duration of the effect. So, the frequency of administration of the drug can be significantly lowered, which constitutes a clear benefit for the patient and also for health providers

Competitive Advantage

The new pharmaceutical compound had greater effect and longer duration of most drugs competitors

Comments on Deal Structure, Potential Terms and Restrictions

The owner prefers to license the patent or make a co-development.

Additional Information

There is an article published on this matter in Cancer Chemotherapy and Pharmacology. Click 'Tell Me More' and request a link to this article.

Patent Summary

U.S. Patent Classes & Classifications Covered in this listing:

Class 424: Drug, Bio-Affecting And Body Treating Compositions

This class includes the following subject matter, not provided for elsewhere: 1. Drug and bio-affecting compositions which are capable of: preventing, alleviating, treating, or curing abnormal and pathological conditions of the living body; maintaining, increasing, decreasing, limiting, or destroying a physiologic body function; diagnosing a physiological condition or state by an in vivo test; controlling or protecting an environment or living body by attracting, disabling, inhibiting, killing, modifying, repelling or retarding an animal or micro-organism. 2. Body treating compositions generally intended for deodorizing, protecting, adorning, or grooming a body. 3. Fermentates. Plant and animal extracts, or body fluids or material containing plant or animal cellular structure. 4. Compositions of this class defined in terms of specific structure; e.g., layered tablet, capsule. 5. Processes of using or preparing subject matter of the Class Definition.


View this listing on the Tynax website: www.tynax.com/listing/5884